A detailed history of Vantage Consulting Group Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Vantage Consulting Group Inc holds 1,379 shares of ABBV stock, worth $267,912. This represents 0.39% of its overall portfolio holdings.

Number of Shares
1,379
Previous 1,330 3.68%
Holding current value
$267,912
Previous $242,000 2.48%
% of portfolio
0.39%
Previous 0.36%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $7,584 - $8,857
49 Added 3.68%
1,379 $236,000
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $37,877 - $43,157
-237 Reduced 15.12%
1,330 $242,000
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $1,238 - $1,394
9 Added 0.58%
1,567 $242,000
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $14,561 - $16,856
-109 Reduced 6.54%
1,558 $232,000
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $8,878 - $11,048
67 Added 4.19%
1,667 $224,000
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $16,485 - $18,985
114 Added 7.67%
1,600 $254,000
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $45,918 - $55,068
-332 Reduced 18.26%
1,486 $240,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $19,326 - $22,165
144 Added 8.6%
1,818 $244,000
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $18,578 - $23,619
135 Added 8.77%
1,674 $256,000
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $70,345 - $87,278
-533 Reduced 25.72%
1,539 $249,000
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $22,023 - $27,865
-205 Reduced 9.0%
2,072 $281,000
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $33,941 - $38,528
319 Added 16.29%
2,277 $246,000
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $206,001 - $229,497
1,958 New
1,958 $221,000
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $70,280 - $77,369
-687 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $55,296 - $74,656
687 New
687 $74,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Vantage Consulting Group Inc Portfolio

Follow Vantage Consulting Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.